Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kaneez Zahra Rubab Khakwani"'
Autor:
Scott French, Juan Arias, MD, Ikeoluwapo Bolakale-Rufai, MD, Summan Zahra, MD, Kaneez Zahra Rubab Khakwani, MD, Edward J. Bedrick, PhD, Geidy E. Serrano, PhD, Thomas G. Beach, MD, PhD, Eric Reiman, MD, Craig Weinkauf, MD, PhD
Publikováno v:
JVS - Vascular Science, Vol 5, Iss , Pp 100206- (2024)
Objective: Stroke and transient ischemic attack may have long-term negative effects on the blood-brain barrier (BBB) and promote endothelial inflammation, both of which could increase neurodegeneration and dementia risk beyond the cell death associat
Externí odkaz:
https://doaj.org/article/95822acc6ea84fca99533b10359d0057
Autor:
Irbaz B. Riaz, Mahnoor Islam, Ahsan Masood Khan, Syed Arsalan Ahmed Naqvi, Rabbia Siddiqi, Kaneez Zahra Rubab Khakwani, Noureen Asghar, Waleed Ikram, Syed A. Hussain, Parminder Singh, Jeremy L. Warner, Guru P. Sonpavde, Folakemi T. Odedina, Kenneth L. Kehl, Narjust Duma, Alan H. Bryce
Publikováno v:
The American journal of medicine. 135(8)
We aim to describe reporting and representation of minority patient populations in immune checkpoint inhibitor (ICI) clinical trials and assess predictors of enrollment disparity.Trial-level data were acquired from eligible phase II and III trials. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190cb811379c5ccdb77cde2603cd6a6e
https://pubmed.ncbi.nlm.nih.gov/35483426
https://pubmed.ncbi.nlm.nih.gov/35483426
Autor:
Anum Riaz, Yusra Saleem, Syed Arsalan Ahmed Naqvi, Mahnoor Islam, Syeda Zainab Kazmi, Kaneez Zahra Rubab Khakwani, Safi U. Khan, Parminder Singh, Emad Hammode, Irbaz Bin Riaz, Alan Haruo Bryce
Publikováno v:
Journal of Clinical Oncology. 41:116-116
116 Background: The impact of socioeconomic status on genitourinary (GU) cancer mortality in the United States (US) is unclear. Hence, we evaluated the association of the socioeconomic status with GU cancer mortality across the US counties. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bbb232e91a59b2f2b8e7b5db011e568
https://doi.org/10.1200/jco.2023.41.6_suppl.116
https://doi.org/10.1200/jco.2023.41.6_suppl.116
Autor:
Syed Arsalan Ahmed Naqvi, Huan He, Rabbia Siddiqi, Nihal Ijaz Khan, Kaneez Zahra Rubab Khakwani, Ahsan Ayaz, Parminder Singh, Thai Huu Ho, Alan Haruo Bryce, Bradley Alexander McGregor, Wenxin (Vincent) Xu, Irbaz Bin Riaz
Publikováno v:
Journal of Clinical Oncology. 41:695-695
695 Background: Recent results from COSMIC 313 trial and updated findings from other contemporary trials have added to the existing body of evidence for 1L mRCC. Therefore, we present the most up-to-date results from our living, interactive systemati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0194512733e6bd47922b9aad1d0454a
https://doi.org/10.1200/jco.2023.41.6_suppl.695
https://doi.org/10.1200/jco.2023.41.6_suppl.695
Autor:
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Mahnoor Islam, Waleed Ikram, Kaneez Zahra Rubab Khakwani, Hafsah Ijaz, Ahsan Ayaz, Parminder Singh, Alan Haruo Bryce
Publikováno v:
Journal of Clinical Oncology. 41:40-40
40 Background: Previously we have reported enrollment disparities in PCa clinical trials. Funding source can influence minority representation in clinical trials. Hence, we aimed to evaluate the impact of source of funding on enrollment disparities i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89d49e2542106079cfb69f965adaf171
https://doi.org/10.1200/jco.2023.41.6_suppl.40
https://doi.org/10.1200/jco.2023.41.6_suppl.40
Autor:
Ahsan Ayaz, Syed Arsalan Ahmed Naqvi, Mahnoor Islam, Waleed Ikram, Umar Raza, Anum Riaz, Kaneez Zahra Rubab Khakwani, Hafsah Ijaz, Bassam Bassam Sonbol, Zhaohui Jin, Irbaz Bin Riaz
Publikováno v:
Journal of Clinical Oncology. 41:23-23
23 Background: Identification of factors associated with enrollment disparities in clinical trials can narrow cancer care inequities. Funding source can influence minority representation in clinical trials. Therefore, we aimed to assess the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b16536410ac3f6cb341d678414d6e9e6
https://doi.org/10.1200/jco.2023.41.4_suppl.23
https://doi.org/10.1200/jco.2023.41.4_suppl.23
Autor:
Waleed Ikram, Syed Arsalan Ahmed Naqvi, Ammad Raina, Ezza Fatima, Rabbia Siddiqi, Mahnoor Islam, Noureen Asghar, Kaneez Zahra Rubab Khakwani, Ahsan Masood Khan, Syed A. Hussain, Alan Haruo Bryce, Irbaz Bin Riaz, Parminder Singh
Publikováno v:
Journal of Clinical Oncology. 40:4594-4594
4594 Background: Cisplatin based neoadjuvant chemotherapy (NAC) followed by definitive therapy improves survival in patients with muscle invasive bladder cancer (MIBC). However, the clinical benefit of NAC might vary with the choice of definitive the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5162eac965be732633022baaab611525
https://doi.org/10.1200/jco.2022.40.16_suppl.4594
https://doi.org/10.1200/jco.2022.40.16_suppl.4594
Autor:
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Waleed Ikram, Rabbia Siddiqi, Noureen Asghar, Kaneez Zahra Rubab Khakwani, Atiqa Khalid, Syed A. Hussain, Parminder Singh, Alan Haruo Bryce
Publikováno v:
Journal of Clinical Oncology. 40:132-132
132 Background: Treatment landscape for metastatic castration-sensitive prostate cancer (mCSPC) is rapidly evolving. Recent updates of relevant trials and presentation of PEACE-1 results warranted mixed treatment comparisons to inform the choice of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41fed9d8dbbdc79cab954d33f68e0675
https://doi.org/10.1200/jco.2022.40.6_suppl.132
https://doi.org/10.1200/jco.2022.40.6_suppl.132
Autor:
Waleed Ikram, Syed Arsalan Ahmed Naqvi, Ezza Fatima, Rabbia Siddiqi, Mahnoor Islam, Noureen Asghar, Kaneez Zahra Rubab Khakwani, Ahsan Masood Khan, Wenxin Xu, Syed A. Hussain, Guru P. Sonpavde, Alan Haruo Bryce, Irbaz Bin Riaz, Parminder Singh
Publikováno v:
Journal of Clinical Oncology. 40:518-518
518 Background: Cisplatin (C) based neoadjuvant chemotherapy (NAC) has been the mainstay treatment for muscle invasive bladder cancer (MIBC). However, the optimal choice of NAC is not well-established. We therefore conducted a network-meta-analysis (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f90d8a517f0b4b1b9a6e46103888cff0
https://doi.org/10.1200/jco.2022.40.6_suppl.518
https://doi.org/10.1200/jco.2022.40.6_suppl.518